Top

Published in:

Open Access 01-12-2023 | Research

Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study

Authors: Yao-Ge Liu, Shi-Tao Jiang, Lei Zhang, Han Zheng, Ting Zhang, Jun-Wei Zhang, Hai-Tao Zhao, Xin-Ting Sang, Yi-Yao Xu, Xin Lu

Published in: European Journal of Medical Research | Issue 1/2023

Abstract

Background

As the complexity and diversity of the tumor immune microenvironment (TIME) are becoming better understood, burgeoning research has progressed in this field. However, there is a scarcity of literature specifically focused on the bibliometric analysis of this topic. This study sought to investigate the development pattern of TIME-related research from 2006 to September 14, 2022, from a bibliometric perspective.

Methods

We acquired both articles and reviews related to TIME from the Web of Science Core Collection (WoSCC) (retrieved on September 14, 2022). R package “Bibliometrix” was used to calculate the basic bibliometric features, present the collaborative conditions of countries and authors, and generate a three-field plot to show the relationships among authors, affiliations, and keywords. VOSviewer was utilized for co-authorship analysis of country and institution and keyword co-occurrence analysis. CiteSpace was used for citation burst analysis of keywords and cited references. In addition, Microsoft Office Excel 2019 was used to develop an exponential model to fit the cumulative publication numbers.

Results

A total of 2545 publications on TIME were included, and the annual publication trend exhibited a significant increase over time. China and Fudan University were the most productive country and institution, with the highest number of publications of 1495 and 396, respectively. Frontiers in Oncology held the highest number of publications. A number of authors were recognized as the main contributors in this field. The clustering analysis revealed six clusters of keywords that highlighted the research hot spots in the fields of basic medical research, immunotherapy, and various cancer types separately.

Conclusions

This research analyzed 16 years of TIME-related research and sketched out a basic knowledge framework that includes publications, countries, journals, authors, institutions, and keywords. The finding revealed that the current research hot spots of the TIME domain lie in “TIME and cancer prognosis”, “cancer immunotherapy”, and “immune checkpoint”. Our researchers identified the following areas: “immune checkpoint-based immunotherapy”, “precise immunotherapy” and “immunocyte pattern”, which may emerge as frontiers and focal points in the upcoming years, offering valuable avenues for further exploration.

Available only for authorised users

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46. https://doi.org/10.1158/2159-8290.CD-21-1059.CrossRefPubMed

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541–50. https://doi.org/10.1038/s41591-018-0014-x.CrossRefPubMedPubMedCentral

Evans RA, Diamond MS, Rech AJ, Chao T, Richardson MW, Lin JH, Bajor DL, et al. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. JCI Insight. 2016. https://doi.org/10.1172/jci.insight.88328.CrossRefPubMedPubMedCentral

Mlecnik B, Bindea G, Angell HK, Maby P, Angelova M, Tougeron D, Church SE, et al. Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability. Immunity. 2016;44:698–711. https://doi.org/10.1016/j.immuni.2016.02.025.CrossRefPubMed

Li J, Yuan S, Norgard RJ, Yan F, Sun YH, Kim IK, Merrell AJ, et al. Epigenetic and transcriptional control of the epidermal growth factor receptor regulates the tumor immune microenvironment in pancreatic cancer. Cancer Discov. 2021;11:736–53. https://doi.org/10.1158/2159-8290.CD-20-0519.CrossRefPubMed

Chen Y, Zheng X, Wu C. The role of the tumor microenvironment and treatment strategies in colorectal cancer. Front Immunol. 2021;12: 792691. https://doi.org/10.3389/fimmu.2021.792691.CrossRefPubMedPubMedCentral

Dieu-Nosjean MC, Giraldo NA, Kaplon H, Germain C, Fridman WH, Sautes-Fridman C. Tertiary lymphoid structures, drivers of the anti-tumor responses in human cancers. Immunol Rev. 2016;271:260–75. https://doi.org/10.1111/imr.12405.CrossRefPubMed

Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med. 2006;203:1651–6. https://doi.org/10.1084/jem.20051848.CrossRefPubMedPubMedCentral

Khalili JS, Liu S, Rodriguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012;18:5329–40. https://doi.org/10.1158/1078-0432.CCR-12-1632.CrossRefPubMedPubMedCentral

10.

Fassoulaki A, Tsaroucha A, Micha G, Soulioti E. Bibliometric analysis of alternative performance metrics for peri-operative, critical care and pain medicine journals. Anaesthesia. 2021;76:856–7. https://doi.org/10.1111/anae.15444.CrossRefPubMed

11.

Ho WJ, Danilova L, Lim SJ, Verma R, Xavier S, Leatherman JM, Sztein MB, et al. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. J Immunother Cancer. 2020. https://doi.org/10.1136/jitc-2019-000394.CrossRefPubMedPubMedCentral

12.

Ding Z, Dong Z, Chen Z, Hong J, Yan L, Li H, Yao S, et al. Viral status and efficacy of immunotherapy in hepatocellular carcinoma: a systematic review with meta-analysis. Front Immunol. 2021;12: 733530. https://doi.org/10.3389/fimmu.2021.733530.CrossRefPubMedPubMedCentral

13.

Wang S, Zhou H, Zheng L, Zhu W, Zhu L, Feng D, Wei J, et al. Global trends in research of macrophages associated with acute lung injury over past 10 years: a bibliometric analysis. Front Immunol. 2021;12: 669539. https://doi.org/10.3389/fimmu.2021.669539.CrossRefPubMedPubMedCentral

14.

de CastilhosGhisi N, Zuanazzi NR, Fabrin TMC, Oliveira EC. Glyphosate and its toxicology: a scientometric review. Sci Total Environ. 2020;733: 139359. https://doi.org/10.1016/j.scitotenv.2020.139359.CrossRef

15.

Wu K, Liu Y, Liu L, Peng Y, Pang H, Sun X, Xia D. Emerging trends and research foci in tumor microenvironment of pancreatic cancer: a bibliometric and visualized study. Front Oncol. 2022;12: 810774. https://doi.org/10.3389/fonc.2022.810774.CrossRefPubMedPubMedCentral

16.

Chen P, Du Z, Wang J, Liu Y, Zhang J, Liu D. A bibliometric analysis of the research on hematological tumor microenvironment. Ann Transl Med. 2021;9:1337. https://doi.org/10.21037/atm-21-3924.CrossRefPubMedPubMedCentral

17.

Zhang Y, Huo L, Wei Z, Tang Q, Sui H. Hotspots and frontiers in inflammatory tumor microenvironment research: a scientometric and visualization analysis. Front Pharmacol. 2022;13: 862585. https://doi.org/10.3389/fphar.2022.862585.CrossRefPubMedPubMedCentral

18.

Shen H, Wang L, Zhang Y, Huang G, Liu B. Knowledge mapping of image-guided tumor ablation and immunity: a bibliometric analysis. Front Immunol. 2023;14:1073681. https://doi.org/10.3389/fimmu.2023.1073681.CrossRefPubMedPubMedCentral

19.

Zhou F, Liu Y, Liu C, Wang F, Peng J, Xie Y, Zhou X. Knowledge landscape of tumor-associated macrophage research: a bibliometric and visual analysis. Front Immunol. 2023;14:1078705. https://doi.org/10.3389/fimmu.2023.1078705.CrossRefPubMedPubMedCentral

20.

Meho LI, Yang K. Impact of data sources on citation counts and rankings of LIS faculty: web of science versus scopus and google scholar. J Am Soc Inform Sci Technol. 2007;58:2105–25.CrossRef

21.

You Y, Li W, Liu J, Li X, Fu Y, Ma X. Bibliometric review to explore emerging high-intensity interval training in health promotion: a new century picture. Front Public Health. 2021;9: 697633. https://doi.org/10.3389/fpubh.2021.697633.CrossRefPubMedPubMedCentral

22.

You Y, Wang D, Liu J, Chen Y, Ma X, Li W. Physical exercise in the context of air pollution: an emerging research topic. Front Physiol. 2022;13: 784705. https://doi.org/10.3389/fphys.2022.784705.CrossRefPubMedPubMedCentral

23.

You Y, Wang D, Wang Y, Li Z, Ma X. A bird’s-eye view of exercise intervention in treating depression among teenagers in the last 20 years: a bibliometric study and visualization analysis. Front Psychiatry. 2021;12: 661108. https://doi.org/10.3389/fpsyt.2021.661108.CrossRefPubMedPubMedCentral

24.

Jiang ST, Liu YG, Zhang L, Sang XT, Xu YY, Lu X. Immune-related adverse events: a bibliometric analysis. Front Immunol. 2022;13:1096806. https://doi.org/10.3389/fimmu.2022.1096806.CrossRefPubMedPubMedCentral

25.

Sood SK, Rawat KS, Kumar D. Analytical mapping of information and communication technology in emerging infectious diseases using CiteSpace. Telemat Inform. 2022;69: 101796. https://doi.org/10.1016/j.tele.2022.101796.CrossRefPubMedPubMedCentral

26.

Sood SK, Rawat KS, Kumar D. A visual review of artificial intelligence and Industry 4.0 in healthcare. Comput Electr Eng. 2022;101: 107948. https://doi.org/10.1016/j.compeleceng.2022.107948.CrossRefPubMedPubMedCentral

27.

van den Hoven AF, Keijsers RGM, Lam M, Glaudemans A, Verburg FA, Vogel WV, Lavalaye J. Current research topics in FAPI theranostics: a bibliometric analysis. Eur J Nucl Med Mol Imaging. 2023;50:1014–27. https://doi.org/10.1007/s00259-022-06052-9.CrossRefPubMed

28.

Chadegani AA, Salehi H, Yunus MM, Farhadi H, Fooladi M, Farhadi M, Ebrahim NA. A comparison between two main academic literature collections: web of science and scopus databases. Asian Soc Sci. 2013. https://doi.org/10.5539/ass.v9n5p18.CrossRef

29.

Team RC. R: a language and environment for statistical computing. R Foundation for Statistical Computing; 2013. https://www.R-project.org/.

30.

van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523–38. https://doi.org/10.1007/s11192-009-0146-3.CrossRefPubMed

31.

Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol. 2006;57(3):359–77. https://doi.org/10.1002/asi.20317.CrossRef

32.

van Eck NJ, Waltman L. Citation-based clustering of publications using CitNetExplorer and VOSviewer. Scientometrics. 2017;111:1053–70. https://doi.org/10.1007/s11192-017-2300-7.CrossRefPubMedPubMedCentral

33.

van Eck NJ, Waltman L, van Raan AF, Klautz RJ, Peul WC. Citation analysis may severely underestimate the impact of clinical research as compared to basic research. PLoS ONE. 2013;8: e62395. https://doi.org/10.1371/journal.pone.0062395.CrossRefPubMedPubMedCentral

34.

Venable GT, Shepherd BA, Loftis CM, McClatchy SG, Roberts ML, Fillinger ME, Tansey JB, et al. Bradford’s law: identification of the core journals for neurosurgery and its subspecialties. J Neurosurg. 2016;124:569–79. https://doi.org/10.3171/2015.3.JNS15149.CrossRefPubMed

35.

Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 2013;14:207–15. https://doi.org/10.1016/j.chom.2013.07.007.CrossRefPubMedPubMedCentral

36.

Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124:687–95. https://doi.org/10.1172/JCI67313.CrossRefPubMedPubMedCentral

37.

Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, et al. Organoid modeling of the tumor immune microenvironment. Cell. 2018;175:1972-1988.e1916. https://doi.org/10.1016/j.cell.2018.11.021.CrossRefPubMedPubMedCentral

38.

De Henau O, Rausch M, Winkler D, Campesato LF, Liu C, Cymerman DH, Budhu S, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature. 2016;539:443–7. https://doi.org/10.1038/nature20554.CrossRefPubMedPubMedCentral

39.

Rodell CB, Arlauckas SP, Cuccarese MF, Garris CS, Li R, Ahmed MS, Kohler RH, et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy. Nat Biomed Eng. 2018;2:578–88. https://doi.org/10.1038/s41551-018-0236-8.CrossRefPubMedPubMedCentral

40.

Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501. https://doi.org/10.1038/ncomms10501.CrossRefPubMedPubMedCentral

41.

DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1:54–67. https://doi.org/10.1158/2159-8274.CD-10-0028.CrossRefPubMedPubMedCentral

42.

Senbabaoglu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 2016;17:231. https://doi.org/10.1186/s13059-016-1092-z.CrossRefPubMedPubMedCentral

43.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. https://doi.org/10.1056/NEJMoa1200690.CrossRefPubMedPubMedCentral

44.

Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018;391:2128–39. https://doi.org/10.1016/S0140-6736(18)30789-X.CrossRefPubMed

45.

Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1. https://doi.org/10.1126/scisignal.2004088.CrossRefPubMedPubMedCentral

46.

Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, Nair VS, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–45. https://doi.org/10.1038/nm.3909.CrossRefPubMedPubMedCentral

47.

Lerman TT, Reitblat O, Reitblat T. Scientific productivity in rheumatology among countries of the organisation for economic co-operation and development and its correlation to national economic indicators. J Clin Rheumatol. 2021;27:92–6. https://doi.org/10.1097/RHU.0000000000001182.CrossRefPubMed

48.

Sun HL, Bai W, Li XH, Huang H, Cui XL, Cheung T, Su ZH, et al. Schizophrenia and inflammation research: a bibliometric analysis. Front Immunol. 2022;13: 907851. https://doi.org/10.3389/fimmu.2022.907851.CrossRefPubMedPubMedCentral

49.

National Bureau of Statistics. Health expenditures in China; 2020. https://data.stats.gov.cn/easyquery.htm?cn=C01.

50.

Shen J, Shen H, Ke L, Chen J, Dang X, Liu B, Hua Y. Knowledge mapping of immunotherapy for hepatocellular carcinoma: a bibliometric study. Front Immunol. 2022;13: 815575. https://doi.org/10.3389/fimmu.2022.815575.CrossRefPubMedPubMedCentral

51.

Xu Q, Chen S, Hu Y, Huang W. Landscape of immune microenvironment under immune cell infiltration pattern in breast cancer. Front Immunol. 2021;12: 711433. https://doi.org/10.3389/fimmu.2021.711433.CrossRefPubMedPubMedCentral

52.

Yu L, Ding Y, Wan T, Deng T, Huang H, Liu J. Significance of CD47 and its association with tumor immune microenvironment heterogeneity in ovarian cancer. Front Immunol. 2021;12: 768115. https://doi.org/10.3389/fimmu.2021.768115.CrossRefPubMedPubMedCentral

53.

Hiltbrunner S, Mannarino L, Kirschner MB, Opitz I, Rigutto A, Laure A, Lia M, et al. Tumor immune microenvironment and genetic alterations in mesothelioma. Front Oncol. 2021;11: 660039. https://doi.org/10.3389/fonc.2021.660039.CrossRefPubMedPubMedCentral

54.

Yang J, Hong S, Zhang X, Liu J, Wang Y, Wang Z, Gao L, et al. Tumor immune microenvironment related gene-based model to predict prognosis and response to compounds in ovarian cancer. Front Oncol. 2021;11: 807410. https://doi.org/10.3389/fonc.2021.807410.CrossRefPubMedPubMedCentral

55.

Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153–67. https://doi.org/10.1038/nri.2017.108.CrossRefPubMed

56.

Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291:319–22. https://doi.org/10.1126/science.291.5502.319.CrossRefPubMed

57.

Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA. 2002;99:12293–7. https://doi.org/10.1073/pnas.192461099.CrossRefPubMedPubMedCentral

58.

Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64. https://doi.org/10.1038/nrc3239.CrossRefPubMedPubMedCentral

59.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65. https://doi.org/10.1056/NEJMoa1200694.CrossRefPubMedPubMedCentral

60.

Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28. https://doi.org/10.1056/NEJMoa1501824.CrossRefPubMed

61.

Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III Trial. J Clin Oncol. 2020;38:193–202. https://doi.org/10.1200/JCO.19.01307.CrossRefPubMed

62.

Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20:5064–74. https://doi.org/10.1158/1078-0432.CCR-13-3271.CrossRefPubMedPubMedCentral

63.

Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T, Plimack ER, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–92. https://doi.org/10.1016/S1470-2045(17)30616-2.CrossRefPubMed

64.

Hui R, Garon EB, Goldman JW, Leighl NB, Hellmann MD, Patnaik A, Gandhi L, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017;28:874–81. https://doi.org/10.1093/annonc/mdx008.CrossRefPubMedPubMedCentral

65.

Daud AI, Wolchok JD, Robert C, Hwu WJ, Weber JS, Ribas A, Hodi FS, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34:4102–9. https://doi.org/10.1200/JCO.2016.67.2477.CrossRefPubMedPubMedCentral

66.

Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18:60. https://doi.org/10.1186/s12943-019-0974-6.CrossRefPubMedPubMedCentral

67.

Huang Y, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18:195–203. https://doi.org/10.1038/nri.2017.145.CrossRefPubMedPubMedCentral

68.

Schaer DA, Beckmann RP, Dempsey JA, Huber L, Forest A, Amaladas N, Li Y, et al. The CDK4/6 inhibitor abemaciclib induces a T cell inflamed tumor microenvironment and enhances the efficacy of PD-L1 checkpoint blockade. Cell Rep. 2018;22:2978–94. https://doi.org/10.1016/j.celrep.2018.02.053.CrossRefPubMed

69.

Mok TSK, Wu YL, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–30. https://doi.org/10.1016/S0140-6736(18)32409-7.CrossRefPubMed

70.

Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med. 2020;383:1328–39. https://doi.org/10.1056/NEJMoa1917346.CrossRefPubMed

71.

Sezer A, Kilickap S, Gumus M, Bondarenko I, Ozguroglu M, Gogishvili M, Turk HM, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397:592–604. https://doi.org/10.1016/S0140-6736(21)00228-2.CrossRefPubMed

72.

Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015;16:141–51. https://doi.org/10.1016/S1470-2045(14)71173-8.CrossRefPubMed

73.

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13:239–46. https://doi.org/10.1016/S1470-2045(11)70393-X.CrossRefPubMed

74.

Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:1454–66. https://doi.org/10.1016/S1470-2045(17)30608-3.CrossRefPubMed

75.

Isomoto K, Haratani K, Hayashi H, Shimizu S, Tomida S, Niwa T, Yokoyama T, et al. Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer. Clin Cancer Res. 2020;26:2037–46. https://doi.org/10.1158/1078-0432.CCR-19-2027.CrossRefPubMed

76.

Lin K, Cheng J, Yang T, Li Y, Zhu B. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-kappaB. Biochem Biophys Res Commun. 2015;463:95–101. https://doi.org/10.1016/j.bbrc.2015.05.030.CrossRefPubMed

77.

Yang L, He YT, Dong S, Wei XW, Chen ZH, Zhang B, Chen WD, et al. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma. J Immunother Cancer. 2022. https://doi.org/10.1136/jitc-2021-003534.CrossRefPubMedPubMedCentral

78.

Lin T, Zhao P, Jiang Y, Tang Y, Jin H, Pan Z, He H, et al. Blood–brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS Nano. 2016;10:9999–10012. https://doi.org/10.1021/acsnano.6b04268.CrossRefPubMed

79.

Qiao C, Yang J, Shen Q, Liu R, Li Y, Shi Y, Chen J, et al. Traceable nanoparticles with dual targeting and ROS response for RNAi-based immunochemotherapy of intracranial glioblastoma treatment. Adv Mater. 2018;30: e1705054. https://doi.org/10.1002/adma.201705054.CrossRefPubMed

80.

Emens LA. Breast cancer immunotherapy: facts and hopes. Clin Cancer Res. 2018;24:511–20. https://doi.org/10.1158/1078-0432.CCR-16-3001.CrossRefPubMed

81.

Gruosso T, Gigoux M, Manem VSK, Bertos N, Zuo D, Perlitch I, Saleh SMI, et al. Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. J Clin Invest. 2019;129:1785–800. https://doi.org/10.1172/JCI96313.CrossRefPubMedPubMedCentral

82.

Keren L, Bosse M, Marquez D, Angoshtari R, Jain S, Varma S, Yang SR, et al. A structured tumor-immune microenvironment in triple negative breast cancer revealed by multiplexed ion beam imaging. Cell. 2018;174:1373-1387.e1319. https://doi.org/10.1016/j.cell.2018.08.039.CrossRefPubMedPubMedCentral

83.

Marabelle A, Kohrt H, Caux C, Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res. 2014;20:1747–56. https://doi.org/10.1158/1078-0432.CCR-13-2116.CrossRefPubMedPubMedCentral

84.

Solomon B, Young RJ, Bressel M, Urban D, Hendry S, Thai A, Angel C, et al. Prognostic significance of PD-L1(+) and CD8(+) immune cells in HPV(+) oropharyngeal squamous cell carcinoma. Cancer Immunol Res. 2018;6:295–304. https://doi.org/10.1158/2326-6066.CIR-17-0299.CrossRefPubMed

85.

Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, et al. Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images. Cell Rep. 2018;23:181-193.e187. https://doi.org/10.1016/j.celrep.2018.03.086.CrossRefPubMedPubMedCentral

86.

Chen D, Xie J, Fiskesund R, Dong W, Liang X, Lv J, Jin X, et al. Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype. Nat Commun. 2018;9:873. https://doi.org/10.1038/s41467-018-03225-9.CrossRefPubMedPubMedCentral

87.

Lund AW, Wagner M, Fankhauser M, Steinskog ES, Broggi MA, Spranger S, Gajewski TF, et al. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. J Clin Invest. 2016;126:3389–402. https://doi.org/10.1172/JCI79434.CrossRefPubMedPubMedCentral

88.

Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73:2943–8. https://doi.org/10.1158/0008-5472.CAN-12-4354.CrossRefPubMedPubMedCentral

89.

Erkes DA, Cai W, Sanchez IM, Purwin TJ, Rogers C, Field CO, Berger AC, et al. Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis. Cancer Discov. 2020;10:254–69. https://doi.org/10.1158/2159-8290.CD-19-0672.CrossRefPubMed

90.

Shi Y, Lammers T. Combining nanomedicine and immunotherapy. Acc Chem Res. 2019;52:1543–54. https://doi.org/10.1021/acs.accounts.9b00148.CrossRefPubMedPubMedCentral

91.

Kong M, Tang J, Qiao Q, Wu T, Qi Y, Tan S, Gao X, et al. Biodegradable hollow mesoporous silica nanoparticles for regulating tumor microenvironment and enhancing antitumor efficiency. Theranostics. 2017;7:3276–92. https://doi.org/10.7150/thno.19987.CrossRefPubMedPubMedCentral

92.

Xia Y, Rao L, Yao H, Wang Z, Ning P, Chen X. Engineering macrophages for cancer immunotherapy and drug delivery. Adv Mater. 2020;32: e2002054. https://doi.org/10.1002/adma.202002054.CrossRefPubMed

Title: Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study
Authors: Yao-Ge Liu
Shi-Tao Jiang
Lei Zhang
Han Zheng
Ting Zhang
Jun-Wei Zhang
Hai-Tao Zhao
Xin-Ting Sang
Yi-Yao Xu
Xin Lu
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI: https://doi.org/10.1186/s40001-023-01195-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Worldwide productivity and research trend of publications concerning tumor immune microenvironment (TIME): a bibliometric study

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

A predictive model for the risk of sepsis within 30 days of admission in patients with traumatic brain injury in the intensive care unit: a retrospective analysis based on MIMIC-IV database

Low HDL-C can be a biomarker to predict persistent severe AKI in septic patients? A retrospective cohort study

Association between thyroid function and obesity phenotypes in healthy euthyroid individuals: an investigation based on Tehran Thyroid Study

Diagnosis, pathophysiology and preventive strategies for cardiac surgery-associated acute kidney injury: a narrative review

Low m6A modification-mediated upregulation of PLAC8 promotes trophoblast cell invasion and migration in preeclampsia

A comprehensive review of the health benefits of flaxseed oil in relation to its chemical composition and comparison with other omega-3-rich oils